TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03142542
Drug: ZYDENA TAB.75mg(Udenafil 75mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
Study: NCT03142542
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
Study: NCT03605862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for five days
Study: NCT04403503
Drug: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
Normalized name: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
Study: NCT04403503
Drug: Cyanoacrylate, Isobutyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
Study: NCT02630095
Drug: Nadroparin Calcium and Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
Study: NCT03205488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules taken once daily
Study: NCT00681915
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00177307
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
Study: NCT01370681
Drug: Period I : HKB0701 and SLM0807, Period II : CJ30001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01370681
Drug: Period I : CJ30001, Period II : HKB0701 and SLM0807
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00921063
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg capsule, BID for 4 weeks
Study: NCT03737708
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT01460654
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Gel (Fortesta) 40mg daily.
Study: NCT00027014
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00258115
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02541669
Drug: TAK-491 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-491 placebo-matching tablets
Study: NCT01747590
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01191775
Drug: PNT2258
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
Study: NCT01655849
Drug: z160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01655849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03028857
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Study: NCT03028857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Study: NCT02342652
Drug: ASLAN003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Study: NCT02342652
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Study: NCT02947880
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
Study: NCT02947880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
Study: NCT02151994
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02151994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01964547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
Study: NCT02394613
Drug: ANX776
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection
Study: NCT03991013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Study: NCT00686140
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg/day, twice a day, 12 weeks
Study: NCT00686140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day, 12 weeks
Study: NCT00343785
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00343785
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03905512
Drug: KRYSTEXXA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT03747068
Drug: Anti-TNF Drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02509858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with 50μg of placebo, once daily, for two months.
Study: NCT02281266
Drug: nucleoside analog (suggest to use entecavir)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03507998
Drug: CGX1321
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGX1321 capsules for oral administration
Study: NCT01729338
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
Study: NCT04425902
Drug: GSK3640254 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
Study: NCT04425902
Drug: Caffeine 200 mg
Normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine will be available as oral tablets at unit dose strength of 200 mg.
Study: NCT04425902
Drug: Flurbiprofen 100 mg
Normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
Study: NCT03234517
Drug: Vaginal Probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Probiotic
Study: NCT04425902
Drug: Pravastatin 40 mg
Normalized name: pravastatin 40 mg oral tablet
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
Study: NCT01453478
Drug: GSK1325756
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR2 antagonist
Study: NCT04065451
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine in the submucosal injection fluid
Study: NCT00624195
Drug: FDA Approved Antiretroviral Therapy (see list below)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
Study: NCT00602498
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04535531
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically once daily
Study: NCT02233920
Drug: Ventilat® - metered dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00161642
Drug: CMD-193
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01662921
Drug: NPH
Normalized name: ZENPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
Study: NCT03492398
Drug: HY209
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Study: NCT03547206
Drug: RPh201 Cohort A
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Study: NCT03547206
Drug: RPh201 Cohort B
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Study: NCT02659787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02405260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02196259
Drug: Anesthetics, Dissociative
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
Study: NCT00329914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pessaries containing peanut oil
Study: NCT03654781
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
Study: NCT00837044
Drug: Migraine rescue medication of choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine rescue medication of choice
Study: NCT03378297
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid tablets 160 mg x1 orally
Study: NCT02430259
Drug: Weekly INH / RRT given by DOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
Study: NCT02038049
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of VAY736 (10 mg/kg)
Study: NCT02038049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to VAY736
Study: NCT00413283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection.
Study: NCT01681563
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01495884
Drug: non-pegylated liposomal doxorubicon (Myocet™)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00058422
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00058422
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01450748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
Study: NCT02504125
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Study: NCT04496999
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
Study: NCT03671109
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
Study: NCT00771251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
Study: NCT04336748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01714843
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01318590
Drug: EUS procedure with drug injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
Study: NCT01073228
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01073228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03382301
Drug: Ciclosporin A preconditioning before renal artery stenosis dilation
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
Study: NCT03382301
Drug: NaCl preconditioning before renal artery stenosis dilation
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
Study: NCT00778609
Drug: EV/DNG (Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
Study: NCT00778609
Drug: Encapsulated Microgynon + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
Study: NCT02533557
Drug: lidocaine mixed with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
Study: NCT01868555
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT00549666
Drug: Placebo 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 mg once daily during treatment period
Study: NCT02263248
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
Study: NCT04599725
Drug: medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical abortion
Study: NCT02228304
Drug: Eylea® injected intravitreally administered every 8 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
Study: NCT00672386
Drug: JNJ16269110
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg twice daily for 12 weeks
Study: NCT00672386
Drug: JNJ16269110
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg twice daily for 12 weeks
Study: NCT00672386
Drug: JNJ16269110
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg twice daily for 12 weeks
Study: NCT00672386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 12 weeks
Study: NCT01291147
Drug: Levobupivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivicaine 0.5% continous infusion for 48 hours
Study: NCT02551523
Drug: Standard of care combinational antiretroviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03319784
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
Study: NCT04111159
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Study: NCT00000379
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00259922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study: NCT04193501
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
Study: NCT02209012
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levulan PDT given in CP0108
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 12
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain